What Revolution Medicines, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 92 | 168 |
| Total trades | 107 | 222 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 291,236 | 1,003,235 |
| Disposed | 430,206 | 1,047,910 |
| Net activity | −138,970 | −44,675 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Borisy Alexis | Director | Nov 11 | Gift · G | −10,625 | — | — | 2,329,450 |
| Anders Jack | Chief Financial Officer | Nov 11 | Open-market sale · S | −9,889 | $192.84 | −$1.91M | 119,216 |
| Anders Jack | Chief Financial Officer | Nov 11 | Open-market sale · S | −9,486 | $191.94 | −$1.82M | 129,105 |
| Anders Jack | Chief Financial Officer | Nov 11 | Open-market sale · S | −500 | $190.99 | −$95.5K | 138,591 |
| Anders Jack | Chief Financial Officer | Nov 11 | Open-market sale · S | −200 | $189.17 | −$37.8K | 139,091 |
| Anders Jack | Chief Financial Officer | Nov 11 | Open-market sale · S | −600 | $187.34 | −$112K | 139,291 |
| Anders Jack | Chief Financial Officer | Nov 11 | Open-market sale · S | −400 | $186.41 | −$74.6K | 139,891 |
| Anders Jack | Chief Financial Officer | Nov 11 | Open-market sale · S | −800 | $185.04 | −$148K | 140,291 |
| Anders Jack | Chief Financial Officer | Nov 11 | Open-market sale · S | −1,900 | $184.02 | −$350K | 141,091 |
| Anders Jack | Chief Financial Officer | Nov 11 | Open-market sale · S | −2,700 | $182.87 | −$494K | 142,991 |
| Anders Jack | Chief Financial Officer | Nov 11 | Open-market sale · S | −5,776 | $182.09 | −$1.05M | 145,691 |
| Anders Jack | Chief Financial Officer | Nov 11 | Open-market sale · S | −3,499 | $181.04 | −$633K | 151,467 |
| Anders Jack | Chief Financial Officer | Nov 11 | Exercise / conversion · M | +19,850 | $18.56 | +$368K | 154,966 |
| Anders Jack | Chief Financial Officer | Nov 11 | Exercise / conversion · M | +15,900 | $42.45 | +$675K | 135,116 |
| Mancini Anthony | See Remarks | Nov 09 | Open-market sale · S | −811 | $200.00 | −$162K | 39,765 |
| Mancini Anthony | See Remarks | Nov 09 | Exercise / conversion · M | +1 | $102.02 | +$102 | 40,576 |
| Mancini Anthony | See Remarks | Nov 09 | Exercise / conversion · M | +810 | $33.62 | +$27.2K | 40,575 |
| Mancini Anthony | See Remarks | Oct 26 | Open-market sale · S | −2,310 | $186.99 | −$432K | 39,765 |
| Mancini Anthony | See Remarks | Oct 26 | Exercise / conversion · M | +2,310 | $33.62 | +$77.7K | 42,075 |
| Sandler Alan B. | Chief Development Officer | Sep 29 | Open-market sale · S | −301 | $204.72 | −$61.6K | 52,559 |
Loading...